Panelists discuss evolving strategies for managing non–muscle-invasive bladder cancer (NMIBC), highlighting how risk stratification, resource limitations, and emerging therapies like gemcitabine-docetaxel are shaping treatment decisions, while emphasizing the urgent need for predictive tools and biomarkers to guide personalized care.
In “Episode 6” of the EAU Podcast series on “Present and future of diagnostics in PCa”, Assoc. Prof. Rajwa speaks with Prof. Carroll about active…
Introduction:Interest has grown in optimizing radical prostatectomy (RP) pathways for prostate cancer, and RP has been removed from the Centers for Medicare & Medicaid Services…
Study is based on registry data from over 64,000 patients with kidney failure across Europe.
Investigators assessed which aspects of surgical performance during radical prostatectomy improve the chances of good functional outcomes.
A novel urodynamic system, engineered and tested by Cleveland Clinic researchers and physicians, is one step closer to commercialization.
The CHAI biomarker was shown to outperform EAU and AUA stratifications.
Investigators examined the comparative effectiveness of SGLT2 inhibitors and GLP-1 receptor agonists in a real-world setting.
Introduction:Clinic no-shows result in misallocation of health care resources and decreased access to care. There is minimal published data examining factors associated with no-shows for…
Can’t sign in? Forgot your password? If the address matches an existing account you will receive an email with instructions to reset your password. Can’t…
Developed by the Medical Student Membership Workgroup, the Urology Spotlight Series educates medical students about a particular subspecialty within urology, including common cases and procedures.…
